Judy King, ASCO 2022: Highlights in breast cancer clinical trials – DESTINY-Breast04, DESTINY-Breast03, TROPiCS-02, CDK4/6 trial data, MAINTAIN study

DESTINY-Breast04 investigates the use of trastuzumab deruxtecan, in the first randomized clinical trial to show that targeting HER2 provides clinically meaningful benefits for patients with HER2-low metastatic breast cancer (0:10). Dr Judy King (Royal Free Hospital, London, UK) joined touchONCOLOGY to discuss the DESTINY-Breast04 trial results and major highlights in breast cancer presented ASCO 2022. In this interview, Dr King also discusses important data from longer term data presented from DESTINY-Breast03 (1:50), and also the phase 3 TROPiCS-02 trial (03:53), examining sacituzumab govitecan vs physicians’ choice chemotherapy for patients with hormone receptor–positive, HER2-negative advanced breast cancer. Dr King also discusses CDK4/6 trial data (cyclin-dependent kinases 4 and 6) (5:04) and overall survival results, and finally she looks at the phase 2 MAINTAIN study (5:36) which demonstrated the potential benefit of continued CDK 4/6 inhibition with hormone therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer who switched endocrine therapy and received the drug after progression on a CDK 4/6 inhibitor.

ASCO 2022 Abstracts discussed in this interview:

1. Abstract #LBA3: Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study
2. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
3. Abstract #LBA1001: Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer

Disclosures: Judy King discloses advisory boards membership and speakers fee honoraria from Roche, BMS, Lilly, Novartis, Pfizer, ExactSciences, Prosigna/Veracyte, Eisai and Astra Zeneca.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.